User:Mr. Ibrahem/Ixabepilone

Mr. Ibrahem/Ixabepilone
Clinical data
Trade names	Ixempra
Other names	Azaepothilone B, BMS-247550
AHFS/Drugs.com	Monograph
MedlinePlus	a608042
License data	US FDA: Ixabepilone;
Routes of; administration	Intravenous infusion
Drug class	Epothilone, microtubule inhibitor
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	N/A
Protein binding	67 to 77%
Metabolism	Extensive, hepatic, CYP3A4-mediated
Elimination half-life	52 hours
Excretion	Fecal (mostly) and renal
Identifiers
	IUPAC name (1R,5S,6S,7R,10S,14S,16S)-6,10-dihydroxy-1,5,7,; 9,9-pentamethyl-14-[(E)-1-(2-methyl-1,3-thiazol-; 4-yl)prop-1-en-2-yl]-17-oxa-13-azabicyclo[14.1.0]; heptadecane-8,12-dione;
Chemical and physical data
Formula	C27H42N2O5S
Molar mass	506.70 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc3nc(/C=C(\C)[C@@H]1C[C@@H]2O[C@]2(C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)cs3;
	InChI InChI=1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1 ; Key:FABUFPQFXZVHFB-PVYNADRNSA-N ;
	(what is this?) (verify)

Ixabepilone, also known as azaepothilone B, is a medication used to treat breast cancer.^[2]^[1] It is used in people who fail other treatments.^[2] It is used by gradual injection into a vein.^[2]

Common side effects include peripheral neuropathy, tiredness, muscle pain, hair loss, nausea, inflammation of the mouth, diarrhea, and low blood cells.^[3] Other side effects may include allergic reactions, heart attack, and arrhythmia.^[3]^[2] Use in pregnancy many harm the baby.^[3] It is an epothilone and microtubule inhibitor.^[2]

Ixabepilone was approved for medical use in the United States in 2007.^[2] In the United states it costs about 5,200 USD per 45 mg vial as of 2021.^[4] It is sold under the brand name Ixempra.^[3]

References[edit]

^ ^a ^b Mandhare, A; Biradar, S; Gurule, A (August 2016). "Azaepothilone B and its derivatives: a patent review". Expert opinion on therapeutic patents. 26 (8): 891–905. doi:10.1080/13543776.2016.1199688. PMID 27282355.
^ ^a ^b ^c ^d ^e ^f ^g ^h "Ixabepilone Monograph for Professionals". Drugs.com. Archived from the original on 25 July 2021. Retrieved 26 November 2021.
^ ^a ^b ^c ^d ^e "DailyMed - IXEMPRA- ixabepilone kit". dailymed.nlm.nih.gov. Archived from the original on 22 April 2021. Retrieved 1 December 2021.
^ "Ixempra Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 21 January 2021. Retrieved 1 December 2021.

[Bir2016-1] Mandhare, A; Biradar, S; Gurule, A (August 2016). "Azaepothilone B and its derivatives: a patent review". Expert opinion on therapeutic patents. 26 (8): 891–905. doi:10.1080/13543776.2016.1199688. PMID 27282355.

[AHFS2021-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h "Ixabepilone Monograph for Professionals". Drugs.com. Archived from the original on 25 July 2021. Retrieved 26 November 2021.

[PI2021-3] "DailyMed - IXEMPRA- ixabepilone kit". dailymed.nlm.nih.gov. Archived from the original on 22 April 2021. Retrieved 1 December 2021.

[4] "Ixempra Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 21 January 2021. Retrieved 1 December 2021.

[1]

[2]

[3]

[4]